Neumora Therapeutics, Inc. (NMRA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Neumora Therapeutics: Downgrading After Navacaprant Development Setback
Neumora Therapeutics is downgraded from 'Strong Buy' to 'Hold' following KOASTAL-1's failure in the MDD primary endpoint. KOASTAL-2 and KOASTAL-3 studies for navacaprant in MDD have increased enrollment; topline data is expected in Q2 2026, but success remains uncertain. NMRA-511 showed a promising signal in phase 1b for Alzheimer's Disease agitation, with an enhanced effect in patients with elevated anxiety.
Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call Transcript
Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call Transcript
Neumora Therapeutics, Inc. (NMRA) Discusses Positive Phase 1b Results for NMRA-511 in Alzheimer's Disease Agitation Transcript
Neumora Therapeutics, Inc. (NMRA) Discusses Positive Phase 1b Results for NMRA-511 in Alzheimer's Disease Agitation Transcript
Neumora Therapeutics, Inc. (NMRA) Discusses NMRA-215 Preclinical Results and Portfolio Updates, Including Obesity and Alzheimer's Disease Programs Transcript
Neumora Therapeutics, Inc. (NASDAQ:NMRA ) Discusses NMRA-215 Preclinical Results and Portfolio Updates, Including Obesity and Alzheimer's Disease Programs October 27, 2025 8:00 AM EDT Company Participants Helen Rubinstein - Head of Investor Relations Paul Berns Joshua Pinto - President Nicholas Brandon - Chief Scientific Officer Daljit Aurora - Chief Operationg & Development officer Conference Call Participants Myles Minter - William Blair & Company L.L.C., Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Douglas Tsao - H.C.
Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call Transcript
Neumora Therapeutics, Inc. (NASDAQ:NMRA ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Daljit Singh Aurora - Corporate Participant Chief Operationg & Development officer - Corporate Participant Helen Rubinstein - Head of Investor Relations Joshua Pinto - President Michael Lee Milligan - CFO & Principal Accounting Officer Nicholas Brandon - Chief Scientific Officer Paul L. Berns - Chairman & CEO Conference Call Participants Ami Fadia - Needham & Company, LLC, Research Division Douglas Dylan Tsao - H.C.
Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript
Neumora Therapeutics, Inc. (NASDAQ:NMRA ) Q1 2025 Results Conference Call May 12, 2025 4:30 PM ET Company Participants Helen Rubinstein - Vice President of Investor Relations & Communications Paul Berns - Chief Executive Officer Josh Pinto - President Bill Aurora - Chief Operating & Development Officer Mike Milligan - Chief Financial Officer Conference Call Participants Douglas Tsao - H.C. Wainwright Yatin Suneja - Guggenheim Graig Suvannavejh - Mizuho Securities John Boyle - William Blair Operator Ladies and gentlemen, thank you for standing by.
Neumora Therapeutics, Inc. (NMRA) Q4 2024 Earnings Call Transcript
Neumora Therapeutics, Inc. (NASDAQ:NMRA ) Q4 2024 Results Conference Call March 3, 2025 8:00 AM ET Company Participants Helen Rubinstein - Vice President of Investor Relations & Communications Paul Berns - Chief Executive Officer Josh Pinto - President Bill Aurora - Chief Operating & Development Officer Michael Milligan - Chief Financial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Douglas Tsao - H.C. Wainwright Delma Caiati - Guggenheim Paul Matteis - Stifel Sam Lee - Mizuho Tess Romero - JPMorgan Operator Ladies and gentlemen, thank you for standing by.
Neumora Stock Hits Record Low on Depression Drug Study Failure
NMRA stock falls after its experimental depression treatment failed to meet the primary and secondary endpoints in the first of three late-stage studies.
Neumora's depression drug fails trial, sinking shares
CNBC's Angelica Peebles joins 'Power Lunch' to discuss Neumora's depression drug failing its trial results.
Neumora Therapeutics shares plummet as Phase 3 depression drug trial disappoints
Neumora Therapeutics shares tumbled over 83% on Thursday after its experimental drug for major depressive disorder (MDD), navacaprant, failed to demonstrate significant benefits in the pivotal Phase 3 KOASTAL-1 study. The study, one of three replicate trials in Neumora's KOASTAL program, did not meet its primary endpoint of improvement in depressive symptoms as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) after six weeks.
Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals
Neumora Therapeutics (NMRA) shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a late-stage study of its experimental treatment for depression did not meet its goals.
Neumora Therapeutics' stock craters after trial of major depressive disorder fails to meet main goals
News is a setback for the clinical-stage biotech and a drug that proved successful in earlier trials
